- US-based specialty pharmaceutical company Velicept Therapeutics' next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder, the company said.
Solabegron is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.
reviews for anti-muscarinic agents and
beta-3 adrenoceptor agonist
Its lead product, solabegron, is a highly potent and selective
beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.
Oral pharmacotherapies for the treatment of OAB include antimuscarinics such as solifenacin and the beta-3 adrenoceptor ([beta]3AR) agonist mirabegron.
Beta-3 adrenoceptor expression in the human urinary bladder nerve fibers.
- Malvern, Pennsylvania-based specialty pharmaceutical company Velicept Therapeutics has commenced the first of two Phase 2b clinical studies of solabegron, a highly potent and selective
beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome, the company said.